Bevacizumab – USA

Bevacizumab – USA

IPR decision (Mar. 09, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Final Written Decision
IPR2016-01771
09/09/2016
03/16/2017
Hospira Inc.
US 7,622,115
Claims 1–5 are unpatentable
US 7,622,115 (Genentech Inc; Exp: May 28, 2024)
1. A method for treating cancer in a patient comprising administering an effective amount of bevacizumab and assessing the patient for gastrointestinal perforation during treatment with bevacizumab.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved